International Collaborations

Promoting collaboration with international stakeholders in the HIV and other infectious diseases fields is a central theme in EuroVacc’s mission.

Collaboration with ANRS

EuroVacc together with ANRS (Agence nationale de recherches sur le sida et les hépatites virales) have co-sponsored the EV03/ANRSVAC20 trial. This is a phase II trial designed to generate further immunogenicity and safety data of the DNA-C prime and NYVAC-C boost regimen and to define the best immunization schedule.

AfrEVacc

EuroVacc is part of the African-European HIV Vaccine Development Network (AfrEVacc) funded by the EDCTP (European Developing Countries Clinical Trial Partnership). It engages 14 partner organizations in Sub-Saharan Africa and Europe. Its objectives include networking, capacity building in Africa and to undertake a pilot trial of the DNA-C and NYVAC-C combination vaccination regimen in Sub-Saharan Africa in preparation for future efficacy trial.

IDEA

Dissecting the Immunological Interplay between Poverty Related Diseases and Helminth Infections: An African-European Research Initiative (IDEA) is a project with 20 Sub-Sahara African and European consortium members and coordinated by the Centre Hospitalier Universitaire Vaudois. IDEA project will focus its efforts on four primary objectives: a) the worm-induced modulation of the functional and molecular profile of HIV-, TB- and malaria-specific immune responses, b) the impact by worm co-infections on measures of disease activity of PRDs, c) the immunologic markers of worm-, HIV-, TB- and malaria-specific immune responses associated with better control of pathogen replication and disease, and d) the modulation by worm co-infections of vaccine-induced immune responses.

EuroVacc will contribute primarily to the last objective.

The project is currently in contract negotiation with the European Commission.